Current market catalysts

Corteva Announces Definitive Agreement To Form 50/50 Crop Protection Joint Venture With Globachem; Expects Close In Q4 2026

8-K filing — Kura Oncology, Inc. (KURA)

Filed: 2026-09-09 AccNo: 0001193125-26-385881 Size: 142 KB Item 8.01: Other Events

ODDITY Tech Sees Q3 Sales $140.505M vs $122.639M Est

ODDITY Tech (NASDAQ:ODD) sees Q3 sales of $140.505 million vs $122.639 million analyst estimate.

8-K filing — Chewy, Inc. (CHWY)

Filed: 2026-09-09 AccNo: 0001628280-26-061011 Size: 490 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

SailPoint Affirms FY2027 Adj EPS Guidance of $0.30-$0.34 vs $0.32 Est; Affirms FY2027 Sales Guidance of $1.265B-$1.275B vs $1.271B Est

SailPoint (NASDAQ:SAIL) affirms FY2027 Adj EPS guidance from $0.30-$0.34 to $0.30-$0.34 vs $0.32 analyst estimate. Affirms FY2027 sales outlook from $1.265 billion-$1.275 billion to $1.265 billion-$1.275 billion vs

SailPoint Sees Q3 Adj EPS $0.07-$0.08 vs $0.08 Est; Sees Sales $326.000M-$330.000M vs $328.731M Est

SailPoint (NASDAQ:SAIL) is looking for Q3 Adj EPS of $0.07-$0.08 vs $0.08 analyst estimate. sees sales of $326.000 million-$330.000 million vs $328.731 million analyst estimate.

SailPoint Q2 Adj. EPS $0.09 Beats $0.08 Estimate, Sales $308.813M Miss $310.247M Estimate

SailPoint (NASDAQ:SAIL) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.08 by 12.5 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same

8-K filing — NovoCure Ltd (NVCR)

Filed: 2026-09-09 AccNo: 0001645113-26-000068 Size: 138 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Schrödinger Announces Formation Of Tectora, New Biotechnology Company; Tectora Secures $55M Series A Investment From NEA And RA Capital Management

Schrödinger, Inc. (NASDAQ:SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative

Destination XL Group Q2 Adj. EPS $0.05 Beats $0.02 Estimate, Sales $111.556M Miss $117.952M Estimate

Destination XL Group (NASDAQ:DXLG) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. The company reported quarterly sales of $111.556 million which missed

ODDITY Tech Q2 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $180.517M Beat $177.602M Estimate

ODDITY Tech (NASDAQ:ODD) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. This is a 78.26 percent decrease over earnings of $0.92 per share from the same

Sunbelt Rentals Holdings Q1 Adj. EPS $1.18 Beats $1.04 Estimate, Sales $3.115B Beat $2.996B Estimate

Sunbelt Rentals Holdings (NYSE:SUNB) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.04 by 13.46 percent. This is a 20.41 percent increase over earnings of $0.98 per share

Bitcoin-Gold Correlation Hits a 6-Year High: What's Going On?

BTC-gold correlation hits a 6-year high as Bitwise's Andre Dragosch sees institutional demand and dollar weakness fueling BTC's next rally.

Trump's White House Endorsement 'Extremely Positive,' Says Hyperion DeFi CEO: Executive Explains Why HYPE Ownership Is 'Beneficial'

Hyunsu Jung, CEO of Hyperion DeFi, Inc., stressed the company's goal of steadily growing its Hyperliquid reserve, noting that greater HYPE ownership is beneficial.

8-K filing — AEye, Inc. (LIDR)

Filed: 2026-09-09 AccNo: 0001213900-26-098204 Size: 226 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K/A filing — D-Wave Quantum Inc. (QBTS)

Filed: 2026-09-09 AccNo: 0001907982-26-000144 Size: 425 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

REMINDER: PROCEPT BioRobotics Corporation Investors With Significant Losses Must Act By September 22, 2026 - Contact Kirby McInerney LLP

Kirby McInerney LLP is reminding PROCEPT BioRobotics investors of the September 22, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges the company made false statements about handpiece unit sales by concealing an extensive discount program that artificially inflated revenues and created over 10,000 excess units in field inventory. Stock declined significantly following earnings misses and guidance reductions in August, November 2025, and February 2026.

PRCT DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action – PRCT

Rosen Law Firm is notifying investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its sales practices, including use of undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess inventory of over 10,000 units, and made unachievable 2025 guidance. Investors with losses exceeding $100,000 are encouraged to seek counsel.

REMINDER: EquipmentShare.com Inc. Investors With Significant Losses Must Act By September 21, 2026 - Contact Kirby McInerney LLP

Kirby McInerney LLP is reminding EquipmentShare.com Inc. investors of the September 21, 2026 deadline to seek lead plaintiff status in a securities fraud class action. The lawsuit alleges the company made materially false statements regarding undisclosed related-party transactions totaling at least $77 million. Following a short-seller report in June 2026, EquipmentShare's stock declined over 34.5% from its $24.50 IPO price to $16.06.

The EV Brain Drain: Lucid Is Bleeding Talent While Rivian Is Evolving

Rivian's CFO Claire McDonough is departing for GE Vernova after nearly six years, but the transition is orderly and reflects the company's evolution from startup fundraising to mass manufacturing. In contrast, Lucid is experiencing a severe executive exodus under new CEO Silvio Napoli, including the departure of founder Peter Rawlinson, CFO Taoufiq Boussaid, and multiple senior engineers. Lucid's sweeping restructuring, layoffs, and delayed product launches signal deeper troubles, making Rivian appear the more stable long-term EV investment.

Rithm (RITM) Registers a Bigger Fall Than the Market: Important Facts to Note

Rithm (RITM) declined 1.29% to $9.95, underperforming the S&P 500's 0.58% loss. The real estate investment trust faces a projected 5.56% EPS decline for the upcoming quarter, though revenue is expected to rise 33.3% year-over-year. The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 4.46, trading at a discount to its industry average of 11.91.

SEOOnly Launches to Help Businesses Navigate the Biggest Shift in Search Since Google's Founding

SEOOnly, founded by marketing entrepreneur Preeti Kennedy, has launched as a specialist search visibility firm focused on helping businesses adapt to AI-driven search and changing customer discovery patterns. The company operates exclusively on search optimization across traditional search engines and AI platforms like ChatGPT and Gemini, rather than offering SEO as one service among many.

MulticoreWare and Micware Sign MOU to Explore Potential Collaboration in ADAS Performance Optimization and Physical AI at the Edge

Micware Co., Ltd. and MulticoreWare, Inc. have signed a Memorandum of Understanding to explore collaboration on AI solutions for advanced driver assistance systems (ADAS), in-vehicle user experience, and edge AI. The partnership combines Micware's automotive OEM relationships and software expertise with MulticoreWare's capabilities in heterogeneous hardware optimization and AI integration. The MOU, effective until June 8, 2027, covers technical cooperation, physical AI integration, business development in Japan, and joint marketing activities, though no definitive agreements have been concluded.

Nucor (NUE) Declines More Than Market: Some Information for Investors

Nucor stock declined 1.79% on September 8, 2026, underperforming the S&P 500's 0.58% loss and lagging the Basic Materials sector. Despite strong earnings projections showing 107.60% EPS growth and 22.4% revenue growth for the upcoming quarter, the stock has lost 4.93% over the past month. Nucor holds a Zacks Rank #3 (Hold) with a Forward P/E of 14.54, slightly above its industry average.

Lennar (LEN) Registers a Bigger Fall Than the Market: Important Facts to Note

Lennar stock fell 3.84% in the latest trading session, underperforming the broader market. The homebuilder faces headwinds with projected EPS declining 34.5% and revenue down 5.42% for the upcoming quarter. The company carries a Zacks Rank of #4 (Sell) and trades at a premium valuation compared to its industry peers.

American Airlines (AAL) Dips More Than Broader Market: What You Should Know

American Airlines stock fell 1.68% on September 8, 2026, underperforming the S&P 500's 0.58% decline. The airline has lost 12.47% over the past month, significantly trailing the broader market. Upcoming earnings are projected to show a loss of $0.32 per share with an 88.24% year-over-year decline, though revenue is expected to grow 17.77%. The stock holds a Zacks Rank of #3 (Hold), and the airline industry ranks in the bottom 16% of all industries.

SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026

Bristol Myers Squibb's SOTYKTU (deucravacitinib), a first-in-class TYK2 inhibitor, has received FDA approval for psoriatic arthritis in March 2026, expanding its commercial potential beyond plaque psoriasis. The drug demonstrates sustained efficacy with PASI 75 response rates of 67%-73% through five years and over 5,000 patient-years of safety data. Market analysis forecasts SOTYKTU sales across seven major markets through 2034, with growth driven by oral convenience, selective mechanism of action, and potential expansion into additional immune-mediated inflammatory disease indications including lupus, Sjogren's syndrome, and Crohn's disease.

WIX DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Wix.com Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action – WIX

Rosen Law Firm is reminding investors who purchased securities of Wix.com Ltd. (NASDAQ: WIX) between February 19, 2025 and May 12, 2026 of an important September 22, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Wix made false and misleading statements regarding its AI product offerings, overstating their competitiveness and performance while understating development costs, resulting in materially false financial representations.

Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and approximately 29% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Cogent Communications Holdings faces a securities fraud class action lawsuit for allegedly failing to disclose material information about its optical wavelength backlog and demand issues during February 29, 2024 to May 1, 2026. The company allegedly misrepresented customer demand, backlog viability, and financial capacity to maintain its dividend policy. Investors who purchased shares during this period have until September 21, 2026 to file lead plaintiff applications.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is urging investors in Aardvark Therapeutics (AARD) to join a securities class action lawsuit with an October 13, 2026 deadline for lead plaintiff claims. The lawsuit alleges that defendants made materially false statements about the safety and prospects of their drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.